Johnson & Johnson reports Phase 4 STAR trial gains for TREMFYA in axial psoriatic arthritis
Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.
Event / data period:
Published: · Updated:

Johnson & Johnson announced on 20 November 2026 late-breaking 24-week results from the Phase 4 STAR study evaluating TREMFYA, known generically as guselkumab, in biologic-naïve adults with active psoriatic arthritis and axial involvement. The findings are being presented at the Emirates Society for Rheumatology Annual Meeting taking place from 20 to 22 November 2026 in Dubai, United Arab Emirates. According to the company, STAR is the first dedicated randomized, double-blind, placebo-controlled trial designed to prospectively evaluate an interleukin-23 inhibitor specifically in psoriatic arthritis patients whose axial inflammation was confirmed by centrally read magnetic resonance imaging.
Registered as NCT04929210, the multicenter STAR study enrolled 411 participants worldwide who had active psoriatic arthritis, elevated C-reactive protein levels and MRI-confirmed axial inflammation despite prior treatment with non-biologic disease-modifying antirheumatic drugs, apremilast or nonsteroidal anti-inflammatory drugs. The trial consists of a 24-week placebo-controlled treatment period followed by a 24-week active treatment period. Its primary endpoint measured the change from baseline at Week 24 in the Bath Ankylosing Spondylitis Disease Activity Index, or BASDAI, a validated 0-to-10 patient-reported scale assessing spinal pain, stiffness, fatigue, peripheral joint symptoms and localized tenderness.
At Week 24, patients receiving TREMFYA 100 mg every four weeks achieved a mean BASDAI score change of minus 3.3 points, while those receiving TREMFYA every eight weeks recorded a mean change of minus 2.9 points, compared with minus 2.1 points in the placebo group. Johnson & Johnson noted in its release that the every-four-weeks dosing regimen is not approved in the United States. The company also disclosed in an editor's note that change from baseline in the Health Assessment Questionnaire Disability Index was numerically greater with every-eight-weeks dosing than placebo, but did not reach statistical significance.
Secondary composite symptom measures reinforced the primary endpoint findings. On the Ankylosing Spondylitis Disease Activity Score with C-reactive protein, or ASDAS-CRP, which combines patient-reported symptoms with an objective inflammatory blood biomarker, mean changes at Week 24 reached minus 1.5 with every-four-weeks dosing and minus 1.3 with every-eight-weeks dosing, compared with minus 0.8 for placebo. Both active dosing schedules surpassed the internationally recognized threshold of at least 1.1 units for clinically important improvement, reflecting reduced systemic inflammation alongside symptom relief.
Objective imaging assessments provided the most closely watched structural evidence in the trial. Inflammation in the sacroiliac joints, which connect the lower spine to the pelvis, was scored using the Spondyloarthritis Research Consortium of Canada, or SPARCC, MRI index. At Week 24, TREMFYA reduced SPARCC scores by minus 7.1 points in the every-four-weeks arm and minus 5.2 points in the every-eight-weeks arm, compared with minus 2.4 points in the placebo group. Johnson & Johnson reported that these reductions represent more than twice the improvement seen with placebo.
Beyond axial symptoms and imaging outcomes, Johnson & Johnson stated that TREMFYA produced high levels of skin clearance across both dosing regimens, consistent with earlier psoriatic arthritis studies including DISCOVER I, DISCOVER II and APEX. The overall safety profile observed through Week 24 in STAR aligned with the established safety record of guselkumab in psoriatic disease, and investigators identified no new safety signals. Known risks listed in the prescribing information include serious allergic reactions, increased susceptibility to infections including tuberculosis, and potential liver abnormalities requiring monitoring where clinically indicated.
Axial involvement in psoriatic arthritis remains a clinically challenging manifestation because there is still no universally accepted definition or validated classification criteria dedicated solely to axial psoriatic arthritis. Literature cited in the announcement estimates that axial disease affects roughly 5 to 28 percent of patients with early psoriatic arthritis and 25 to 70 percent of those with longer-standing disease, adding chronic back pain, neck stiffness and reduced mobility on top of peripheral joint, skin and nail disease. Prospective trials enrolling exclusively MRI-confirmed axial psoriatic arthritis cohorts have remained scarce.
Mikkel Ostergaard, clinical professor of rheumatology at the University of Copenhagen and chair of the Copenhagen Center for Arthritis Research at Rigshospitalet, who serves as a paid consultant to Johnson & Johnson, said the STAR findings pair patient-reported symptom relief with objective MRI reductions in sacroiliac inflammation to help inform clinical decision-making. David M. Lee, global immunology therapeutic area head at Johnson & Johnson, described the results as establishing dedicated prospective evidence for an IL-23 inhibitor in axial psoriatic arthritis while expanding understanding of the disease's diverse manifestations.
TREMFYA is a fully human monoclonal antibody manufactured by Janssen Biotech that blocks interleukin-23 and binds to CD64 in vitro, though the company notes that the clinical significance of CD64 binding remains unknown. The medicine is already approved in the United States for adults and children aged six years and older weighing at least 40 kilograms with moderate to severe plaque psoriasis or active psoriatic arthritis, as well as for adults with ulcerative colitis and Crohn's disease. Full peer-reviewed publication and results from the subsequent 24-week active treatment period will show how durable the axial and MRI improvements remain over 48 weeks.
Data
Key reported figures
Selected Week 24 efficacy and enrolment figures from the Phase 4 STAR study of TREMFYA in axial psoriatic arthritis.
- Global participants enrolled in Phase 4 STAR study
- 411 patients
- 2026-11-20 · Observed
- Mean Week 24 BASDAI score change with TREMFYA Q4W
- -3.3 points
- 2026-11-20 · Observed
- Mean Week 24 BASDAI score change with TREMFYA Q8W
- -2.9 points
- 2026-11-20 · Observed
- Mean Week 24 SPARCC MRI score change with TREMFYA Q4W
- -7.1 points
- 2026-11-20 · Observed
- Mean Week 24 SPARCC MRI score change with placebo
- -2.4 points
- 2026-11-20 · Observed
Methodology
Figures retain the source's stated endpoints, dosing arms, population and definitions. Negative score changes denote symptom or inflammation reduction from baseline. No missing value is inferred.
Updated:
Subjects and places
Subject proposals
- HealthSuggested
- Preserved editorial category/topic; broad candidate onlywww.prnewswire.com ↗
Geographic references
Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.
- United States · Place role: Coverage · Place type: Country or area · Location precision: RegionalEvidence
- Explicit preserved editorial country/region; no city or national centroid inferredwww.prnewswire.com ↗